As LAT1 overexpression has been correlated with malignant phenotype and proliferation of gliomas, our in-house developed AA could possibly demonstrate value for guiding biopsy, diagnosing primary brain tumor, tumor grading, directing radiotherapy, or even for discriminating between tumor recurrence and radionecrosis post-therapy42,43. This evidence concerns the gene SLC7A5 and glioma.